Abstract:BackgroundAppreciable evidence suggest that dysbiosis in microbiota, reflected in gut microbial imbalance plays a key role in the pathogenesis of neuropsychiatric disorders including depression and inflammatory diseases. Recently, the antidepressant properties of ketamine have gained prominence due to its fast and long lasting effects. Additional uses for ketamine in inflammatory disorders such as irritable bowel syndrome have been suggested. However, ketamine’s exact mechanism of action and potential effects on microbiome is not known. Here, we examined the effects of low dose ketamine, known to induce antidepressant effects, on stool microbiome profile in adult male Wistar rats. Animals (5/group) were injected intraperitoneally with ketamine (2.5 mg/kg) or saline, daily for 7 days and sacrificed on day 8 when intestinal stools were collected and stored at − 80 °C. DNA was extracted from the samples and the 16 S rRNA gene-based microbiota analysis was performed using 16S Metagenomics application.ResultsAt genus–level, ketamine strikingly amplified Lactobacillus, Turicibacter and Sarcina by 3.3, 26 and 42 fold, respectively. Conversely, opportunistic pathogens Mucispirillum and Ruminococcus were reduced by approximately 2.6 and 26 fold, respectively, in ketamine group. Low levels of Lactobacillus and Turicibacter are associated with various disorders including depression and administration of certain species of Lactobacillus ameliorates depressive-like behavior in animal models. Hence, some of the antidepressant effects of ketamine might be mediated through its interaction with these gut bacteria. Additionally, high level of Ruminococcus is positively associated with the severity of irritable bowel syndrome (IBS), and some species of Mucispirillum have been associated with intestinal inflammation. Indirect evidence of anti-inflammatory role of Sarcina has been documented. Hence, some of the anti-inflammatory effects of ketamine and its usefulness in specific inflammatory diseases including IBS may be mediated through its interaction with these latter bacteria.ConclusionOur data suggest that at least some of the antidepressant and anti-inflammatory effects of daily ketamine treatment for 7 days may be mediated via its interaction with specific gut bacteria. These findings further validate the usefulness of microbiome as a target for therapeutic intervention and call for more detailed investigation of microbiome interaction with central mediators of mood and/or inflammatory disorders.

Gut Microbiota is Involved in the Antidepressant-Like Effect of (S)-Norketamine in an Inflammation Model of Depression

Molecular and Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine Enantiomers and Its Metabolites

Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Proteomic Study Reveals The Involvement Of Energy Metabolism In The Fast Antidepressant Effect Of (2r, 6r)-Hydroxy Norketamine

Beneficial Effects of (R)-Ketamine, but Not Its Metabolite (2R,6r)-Hydroxynorketamine, in the Depression-Like Phenotype, Inflammatory Bone Markers, and Bone Mineral Density in a Chronic Social Defeat Stress Model.

Ketamine Exerts Its Sustained Antidepressant Effects Via Cell-Type-specific Regulation of Kcnq2.

Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine

Effects of (S)-ketamine on depression-like behaviors in a chronic variable stress model: a role of brain lipidome

Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration

Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine

Serotonin Transporter and Plasma Membrane Monoamine Transporter Are Necessary for the Antidepressant-Like Effects of Ketamine in Mice

Scaffold hopping of agomelatine leads to enhanced antidepressant effects by modulation of gut microbiota and host immune responses

Immunoregulation and Antidepressant Effect of Ketamine

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism

Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions

Downregulation of Neuregulin 1-ErbB4 Signaling in Parvalbumin Interneurons in the Rat Brain May Contribute to the Antidepressant Properties of Ketamine

Repurposing Ketamine in the Therapy of Depression and Depression-Related Disorders: Recent Advances and Future Potential

BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model

Mir-98-5p Plays a Critical Role in Depression and Antidepressant Effect of Ketamine.

The Involvement of AMPA–ERK1/2–BDNF Pathway in the Mechanism of New Antidepressant Action of Prokinetic Meranzin Hydrate